Brief: Poxel Signs Acquisition Agreement With Deuterx For Drx-065

Poxel SA

30/08/2018 07:09

Aug 30 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL EXPANDS METABOLIC PIPELINE THROUGH STRATEGIC
ACQUISITION
AGREEMENT WITH DEUTERX FOR DRX-065, A NOVEL CLINICAL STAGE DRUG
CANDIDATE FOR NASH, AND OTHER PROGRAMS
    * POXEL EXPANDS METABOLIC PIPELINE THROUGH STRATEGIC
ACQUISITION
AGREEMENT WITH DEUTERX FOR DRX-065, A NOVEL CLINICAL STAGE DRUG
CANDIDATE FOR NASH, AND OTHER PROGRAMS
    * POXEL ACQUIRES EXCLUSIVE, WORLDWIDE OWNERSHIP TO DRX-065
(DEUTERIUM-STABILIZED R-PIOGLITAZONE),
    * ADDITIONAL PROGRAMS, INCLUDING DEUTERATED DRUG CANDIDATES
FOR
METABOLIC, SPECIALTY AND RARE DISEASES, ALSO ACQUIRED FROM
DEUTERX
    * SAYS ILL PAY DEUTERX AN UPFRONT PAYMENT COMPOSED OF EUR
6.8
MILLION (USD 8 MILLION) IN CASH PLUS 1.29 MILLION IN NEW
ORDINARY SHARES OF POXEL COMMON STOCK
    * POXEL PLANS TO ADVANCE PXL770 AND DRX-065, INTO
PROOF-OF-CONCEPT
STUDIES FOR TREATMENT OF NASH IN 2019
    * SAYS GAINS EXCLUSIVE, WORLDWIDE OWNERSHIP TO ADDITIONAL
PROGRAMS

Source text for Eikon:  ID:nBw5mzCPDa 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))